PT790823E - Material libertador de farmaco para compressa ou implante cirurgico - Google Patents

Material libertador de farmaco para compressa ou implante cirurgico

Info

Publication number
PT790823E
PT790823E PT95942410T PT95942410T PT790823E PT 790823 E PT790823 E PT 790823E PT 95942410 T PT95942410 T PT 95942410T PT 95942410 T PT95942410 T PT 95942410T PT 790823 E PT790823 E PT 790823E
Authority
PT
Portugal
Prior art keywords
fibers
surgical implant
drug
compression
carrier
Prior art date
Application number
PT95942410T
Other languages
English (en)
Portuguese (pt)
Inventor
Duncan H Haynes
Ben H Boedeker
Mark D Kline
Original Assignee
Gov U S The As Repr By Secreta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gov U S The As Repr By Secreta filed Critical Gov U S The As Repr By Secreta
Publication of PT790823E publication Critical patent/PT790823E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/622—Microcapsules
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T442/00—Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
    • Y10T442/20—Coated or impregnated woven, knit, or nonwoven fabric which is not [a] associated with another preformed layer or fiber layer or, [b] with respect to woven and knit, characterized, respectively, by a particular or differential weave or knit, wherein the coating or impregnation is neither a foamed material nor a free metal or alloy layer
    • Y10T442/2525—Coating or impregnation functions biologically [e.g., insect repellent, antiseptic, insecticide, bactericide, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
PT95942410T 1994-11-28 1995-11-28 Material libertador de farmaco para compressa ou implante cirurgico PT790823E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/345,889 US5660854A (en) 1994-11-28 1994-11-28 Drug releasing surgical implant or dressing material

Publications (1)

Publication Number Publication Date
PT790823E true PT790823E (pt) 2003-11-28

Family

ID=23356955

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95942410T PT790823E (pt) 1994-11-28 1995-11-28 Material libertador de farmaco para compressa ou implante cirurgico

Country Status (14)

Country Link
US (2) US5660854A (ko)
EP (1) EP0790823B1 (ko)
JP (1) JPH10511019A (ko)
KR (1) KR100382987B1 (ko)
AT (1) ATE244561T1 (ko)
AU (1) AU698113B2 (ko)
CA (1) CA2206259A1 (ko)
DE (1) DE69531254T2 (ko)
DK (1) DK0790823T3 (ko)
ES (1) ES2202382T3 (ko)
MX (1) MX9703912A (ko)
PT (1) PT790823E (ko)
RU (1) RU2176525C2 (ko)
WO (1) WO1996016643A1 (ko)

Families Citing this family (423)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114594A (en) * 1992-01-24 2000-09-05 Societe Precis Method of treating a wound using dressing product with core of alginate fibers
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
BR9508723A (pt) 1994-08-17 1998-01-06 Eth Zuerich Implante método de implantação e dispositivo de aplicação
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
DE69812941T2 (de) * 1997-01-30 2004-02-05 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
US6713527B2 (en) * 1997-02-07 2004-03-30 Queen's University At Kingston Anaesthetic bone cement
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US6589199B1 (en) 1997-08-28 2003-07-08 Boston Scientific Corporation System for implanting a cross-linked polysaccharide fiber and methods of forming and inserting the fiber
AU8913998A (en) 1997-08-28 1999-03-22 Boston Scientific Corporation System for implanting a cross-linked polysaccharide fiber and methods of formingand inserting the fiber
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6605751B1 (en) * 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
US5928174A (en) * 1997-11-14 1999-07-27 Acrymed Wound dressing device
JP2006111636A (ja) * 1997-12-26 2006-04-27 Astellas Pharma Inc 徐放性医薬組成物
EP1079808B1 (en) 1998-05-29 2004-02-11 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
DE19825499C2 (de) * 1998-06-08 2003-07-17 Beiersdorf Ag Wirkstoffhaltige Pflaster
SE514908C2 (sv) * 1998-07-13 2001-05-14 Gs Dev Ab Medel för benrekonstruktion
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
NZ511792A (en) 1998-11-20 2003-08-29 Skyepharma Canada Inc Dispersible phospholipid stabilized microparticles
DE19856668A1 (de) * 1998-12-09 2000-06-15 Aesculap Ag & Co Kg Wirkstoffmatrix in Form eines biologisch resorbierbaren porösen Vlieses, Verfahren zu ihrer Herstellung und Verwendung
US6454787B1 (en) 1998-12-11 2002-09-24 C. R. Bard, Inc. Collagen hemostatic foam
US6361551B1 (en) * 1998-12-11 2002-03-26 C. R. Bard, Inc. Collagen hemostatic fibers
US6143946A (en) * 1998-12-24 2000-11-07 Docter; Joan E. Therapeutic mat
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US20040171323A1 (en) * 1999-02-17 2004-09-02 Shalaby Shalaby W. Antimicrobial, synthetic, fibrous, and tubular medical divices
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US7186260B2 (en) * 1999-04-29 2007-03-06 Hyson Morton I Medicated wrap
DE60031114T2 (de) 1999-06-11 2007-05-03 Cytyc Corp., Marlborough Flüssige gelformulierung zum detektieren von milchkanälen in der brust vor einer chirurgischen ablation des brustgewebes
US6398808B1 (en) * 1999-06-15 2002-06-04 Scimed Life Systems, Inc. Localized delivery of genetic information from biostable materials
US6385491B1 (en) * 1999-10-04 2002-05-07 Medtronic, Inc. Temporary medical electrical lead having biodegradable electrode mounting pad loaded with therapeutic drug
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
GB2357435A (en) * 1999-12-23 2001-06-27 Johnson & Johnson Medical Ltd Absorbent medicinal articles
WO2001049258A2 (en) * 1999-12-30 2001-07-12 Acrymed Methods and compositions for improved delivery devices
US20030095993A1 (en) * 2000-01-28 2003-05-22 Hanne Bentz Gel-infused sponges for tissue repair and augmentation
US6627785B1 (en) * 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6309454B1 (en) * 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
US6521244B1 (en) * 2000-06-13 2003-02-18 Nozomu Kanesaka Body filling material
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US8033983B2 (en) 2001-03-09 2011-10-11 Boston Scientific Scimed, Inc. Medical implant
WO2002071931A1 (en) 2001-03-09 2002-09-19 Scimed Life Systems, Inc. Medical slings
US8187625B2 (en) * 2001-03-12 2012-05-29 Boston Scientific Scimed, Inc. Cross-linked gelatin composition comprising a wetting agent
FR2824470B1 (fr) * 2001-05-11 2003-08-29 Brothier Lab Produit de pansement a ame de fibres en alginate entouree d'une enveloppe
CA2451187C (en) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US20040142013A1 (en) * 2001-07-13 2004-07-22 Flow Focusing, Inc. Implantable orthopedic surgical devices with controlled release antimicrobial component
US20050129732A1 (en) * 2001-07-13 2005-06-16 Flow Focusing, Inc. Biodegradable, antibiotic, controlled release tape
US20070254008A1 (en) * 2001-07-13 2007-11-01 Flow Focusing, Inc. Antibiotic formulation and method of treatment
US20070254009A1 (en) * 2001-07-13 2007-11-01 Flow Focusing, Inc. Antibiotic/bone morphogenic protein formulation and method of treatment
US20060263401A1 (en) * 2001-07-13 2006-11-23 Flow Focusing, Inc. Formulation and Method for Preventing Infection
DE60204158T2 (de) * 2001-10-05 2006-02-02 SurModics, Inc., Eden Prairie Beschichtungen mit immobilisierten partikeln sowie verwendungen derselben
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
US20030099693A1 (en) * 2001-11-02 2003-05-29 Auffret Anthony David Wafer
IL162001A0 (en) 2001-11-14 2005-11-20 Alza Corp Catheter injectable depot compositions and uses thereof
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
US20030153947A1 (en) * 2002-02-14 2003-08-14 Tomoaki Koseki Sternum suture material and its manufacturing method
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP1517684B1 (en) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
US7252837B2 (en) 2002-06-28 2007-08-07 Ethicon, Inc. Hemostatic wound dressing and method of making same
US7279177B2 (en) 2002-06-28 2007-10-09 Ethicon, Inc. Hemostatic wound dressings and methods of making same
US8486426B2 (en) * 2002-07-29 2013-07-16 Kimberly-Clark Worldwide, Inc. Methods and compositions for treatment of dermal conditions
KR20050038008A (ko) 2002-07-31 2005-04-25 알자 코포레이션 주사용 저장형 조성물 및 이의 용도
EP2030611A1 (en) 2002-07-31 2009-03-04 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
EP1572115B1 (en) 2002-11-27 2015-01-21 Ampio Pharmaceuticals, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
CA2509914A1 (en) * 2002-12-11 2004-06-24 Ferrosan A/S Gelatine-based materials as swabs
AU2003259834A1 (en) 2002-12-17 2004-07-29 Boston Scientific Limited Spacer for sling delivery system
US20040185009A1 (en) * 2003-03-19 2004-09-23 Dexcel Pharma Technologies Ltd. Composition and device for treating periodontal diseases
US7019191B2 (en) * 2003-03-25 2006-03-28 Ethicon, Inc. Hemostatic wound dressings and methods of making same
DE10315640A1 (de) * 2003-04-04 2004-10-14 Ignatov, Konstantin Verfahren zur kontrollierten Freisetzung von Komponenten in eine Lösung
WO2004099158A1 (en) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Monocyclic diazodioxide based bcl-2 protein antagonists
US20040248877A1 (en) * 2003-04-30 2004-12-09 Sandeep Gupta Polycyclic diazodioxide-based Bcl-2 protein antagonists and use thereof
JP4847868B2 (ja) * 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
US20090227647A1 (en) * 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US20040243044A1 (en) * 2003-06-02 2004-12-02 Penegor Stephen A. Hemostatic wound dressing
US20040265371A1 (en) 2003-06-25 2004-12-30 Looney Dwayne Lee Hemostatic devices and methods of making same
US7361138B2 (en) 2003-07-31 2008-04-22 Scimed Life Systems, Inc. Bioabsorbable casing for surgical sling assembly
US20050036955A1 (en) * 2003-08-13 2005-02-17 Degould Michael D. Bioresorbable tooth extraction socket dressing
KR20060088543A (ko) * 2003-09-25 2006-08-04 디엠아이 바이오사이언스 인코포레이티드 앤-아실-엘-아스파틱산을 이용하는 방법 및 제품
US9579294B1 (en) * 2004-01-02 2017-02-28 New Medical Technology, Inc Scar tissue dressing
US20080131493A1 (en) * 2004-01-02 2008-06-05 Haitham Matloub Method and Multilayered Device for Controlled Topical Delivery of Therapeutic Agents to the Skin
JP2007519450A (ja) * 2004-01-30 2007-07-19 フェロサン アー／エス 止血用のスプレーおよび組成物
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8467875B2 (en) 2004-02-12 2013-06-18 Medtronic, Inc. Stimulation of dorsal genital nerves to treat urologic dysfunctions
US20090216252A1 (en) * 2004-02-13 2009-08-27 The University Of Cincinnati A coupling device enabled by mechanical continuity of cellular scaffolding across tissue boundaries
CN100558415C (zh) * 2004-02-28 2009-11-11 汉莫堤克科技公司 药物表面的生物相容性涂层、方法和用途
WO2005113523A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2005120578A2 (en) * 2004-06-07 2005-12-22 California Institute Of Technology Biodegradable drug-polymer delivery system
WO2006009876A2 (en) * 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
WO2006080951A2 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US20060002970A1 (en) * 2004-07-01 2006-01-05 Aspenberg Per V Method for coating a suture
EP1786421A2 (en) * 2004-07-09 2007-05-23 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
CN101001649B (zh) * 2004-07-09 2011-08-31 弗罗桑医疗设备公司 包括透明质酸的止血组合物及其制备方法
US8361553B2 (en) 2004-07-30 2013-01-29 Kimberly-Clark Worldwide, Inc. Methods and compositions for metal nanoparticle treated surfaces
CN102783499A (zh) * 2004-07-30 2012-11-21 金伯利-克拉克环球有限公司 抗微生物的装置和组合物
AU2005280443B2 (en) * 2004-07-30 2011-02-03 Avent, Inc. Antimicrobial silver compositions
EP1841749A1 (en) 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
AU2005287137B2 (en) 2004-09-17 2012-03-22 Foldrx Pharmaceuticals, Inc. Compounds, compositions and methods of inhibiting a-synuclein toxicity
US9289378B2 (en) 2004-09-20 2016-03-22 Avent, Inc. Antimicrobial amorphous compositions
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
US20060078589A1 (en) * 2004-10-12 2006-04-13 Jensen Steven D Device for treating oral wound gaps
US9358318B2 (en) 2004-10-20 2016-06-07 Ethicon, Inc. Method of making a reinforced absorbable multilayered hemostatic wound dressing
EP2345430B1 (en) 2004-10-20 2015-11-25 Ethicon, Inc. A reinforced absorbable multilayered fabric for use in medical devices and method of manufacture
WO2006044882A2 (en) * 2004-10-20 2006-04-27 Ethicon, Inc. A reinforced absorbable multilayered hemostatic wound dressing and method of making
FR2877846B1 (fr) * 2004-11-15 2008-12-05 Univ Lille Sciences Tech Biomateriaux porteurs de cyclodextrines aux proprietes d'absorption ameliorees et de liberation progressive et retardee de molecules therapeutiques
AU2005314426A1 (en) 2004-12-10 2006-06-15 Talima Therapeutics, Inc. Compositions and methods for treating conditions of the nail unit
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20070005213A1 (en) * 2005-06-30 2007-01-04 Hyundai Autonet Co., Ltd. Backward control for automobiles using telematics and method thereof
CN101287507B (zh) * 2005-08-12 2012-12-05 刘江 用于淋巴靶向的方法和装置
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US20070110786A1 (en) * 2005-11-15 2007-05-17 Boston Scientific Scimed, Inc. Medical articles having enhanced therapeutic agent binding
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
US8663674B2 (en) * 2006-01-13 2014-03-04 Surmodics, Inc. Microparticle containing matrices for drug delivery
US8795730B2 (en) * 2006-01-31 2014-08-05 David John Vachon Compositions and methods for promoting the healing of tissue of multicellular organisms
US7809443B2 (en) 2006-01-31 2010-10-05 Medtronic, Inc. Electrical stimulation to alleviate chronic pelvic pain
US20070191816A1 (en) * 2006-02-13 2007-08-16 Boston Scientific Scimed, Inc. Radio frequency induced drug elution
AU2007221050B2 (en) * 2006-02-28 2012-08-30 Covidien Lp Antimicrobial medical devices
CN101443314B (zh) * 2006-03-13 2014-04-09 杏林制药株式会社 作为gsk-3抑制剂的氨基喹诺酮类
EA200870385A1 (ru) * 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. Ингибирование токсичности альфа-синуклеина
US7761166B2 (en) * 2006-04-28 2010-07-20 Medtronic, Inc. Electrical stimulation of iliohypogastric nerve to alleviate chronic pelvic pain
US20070253997A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Drug delivery to alleviate chronic pelvic pain
EP2015722B1 (en) 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
US20070255324A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Drug delivery to ilioinguinal nerve to alleviate chronic pelvic pain
US20070255333A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Neuromodulation therapy for perineal or dorsal branch of pudendal nerve
US8219202B2 (en) * 2006-04-28 2012-07-10 Medtronic, Inc. Electrical stimulation of ilioinguinal nerve to alleviate chronic pelvic pain
US7638344B2 (en) * 2006-06-28 2009-12-29 Surmodics, Inc. Active agent eluting matrices with particulates
WO2008006083A2 (en) 2006-07-07 2008-01-10 Surmodics, Inc. Beaded wound spacer device
MX2009002151A (es) 2006-08-28 2009-07-03 Kirin Pharma Kk Anticuerpos monoclonales humanos especificos para light humano antagonistas.
JP2010504333A (ja) * 2006-09-20 2010-02-12 タイコ ヘルスケア グループ リミテッド パートナーシップ 新規のトリクロサン塩
PT2066662E (pt) 2006-09-21 2013-02-13 Kyorin Seiyaku Kk Inibidores de serina-hidrolase
EP2081893B1 (en) 2006-10-19 2011-03-23 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
WO2008077103A1 (en) 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preperation and utility of ccr5 inhibitors
EP2125739A1 (en) * 2006-12-22 2009-12-02 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
PL2144604T3 (pl) * 2007-02-28 2012-02-29 Conatus Pharmaceuticals Inc Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
WO2008109347A2 (en) * 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
DK2125698T3 (en) 2007-03-15 2016-11-07 Auspex Pharmaceuticals Inc Deuterated d9-VENLAFAXINE
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
CN101801188A (zh) * 2007-07-12 2010-08-11 特拉加拉医药品公司 治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物
CN101855228B (zh) * 2007-09-11 2012-10-24 杏林制药株式会社 作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
EP2203459B1 (en) 2007-09-12 2016-03-16 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as gsk-3 inhibitors
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
JP2011504485A (ja) 2007-11-21 2011-02-10 ファーマクシス リミテッド Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途
EP2254605A4 (en) * 2008-02-22 2012-06-20 Celonova Biosciences Inc MULTIFUNCTIONAL MATRICES FOR DRESSINGS AND ASSOCIATED METHODS
CN102014973A (zh) 2008-02-29 2011-04-13 弗罗桑医疗设备公司 用于促进止血和/或伤口愈合的装置
CA2972138A1 (en) 2008-03-17 2009-09-24 Ambit Biosciences Corporation Raf kinase modulator compounds and methods of use thereof
US8496954B2 (en) * 2008-04-18 2013-07-30 Surmodics, Inc. Coating systems for the controlled delivery of hydrophilic bioactive agents
US20110091577A1 (en) * 2008-04-25 2011-04-21 Silverman Lance D Drug release coatings on calcuim phosphate and uses thereof
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
KR20170029019A (ko) * 2008-07-18 2017-03-14 바이오모드 컨셉츠 인코포레이티드 활성 성분을 방출하는 제품
US20120034155A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
KR20110124787A (ko) 2009-02-27 2011-11-17 암비트 바이오사이언시즈 코포레이션 Ｊａｋ 키나아제 조절 퀴나졸린 유도체 및 이의 사용 방법
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
EP2406266B1 (en) * 2009-03-11 2013-12-25 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
JP2012520314A (ja) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン 癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
US20100247600A1 (en) * 2009-03-24 2010-09-30 Warsaw Orthopedic, Inc. Therapeutic drug eluting implant cover and method of making the same
CN102448958B (zh) 2009-03-27 2015-10-21 维特Dc公司 嘧啶基和1,3,5-三嗪基苯并咪唑磺酰胺和其在癌症治疗中的用途
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US9078712B2 (en) 2009-04-15 2015-07-14 Warsaw Orthopedic, Inc. Preformed drug-eluting device to be affixed to an anterior spinal plate
US9414864B2 (en) * 2009-04-15 2016-08-16 Warsaw Orthopedic, Inc. Anterior spinal plate with preformed drug-eluting device affixed thereto
NZ620074A (en) 2009-04-22 2015-09-25 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide ccr3 antagonists
NZ620092A (en) 2009-04-22 2015-07-31 Axikin Pharmaceuticals Inc Arylsulfonamide ccr3 agtagonists
EP2727908A3 (en) 2009-04-22 2014-08-20 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide CCR3 antagonists
US20100274295A1 (en) * 2009-04-24 2010-10-28 Warsaw Orthopedic, Inc. Medical implant configured to deliver a therapeutic substance
US8333791B2 (en) * 2009-04-24 2012-12-18 Warsaw Orthopedic, Inc. Medical implant with tie configured to deliver a therapeutic substance
US10806833B1 (en) * 2009-05-11 2020-10-20 Integra Lifesciences Corporation Adherent resorbable matrix
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CA2767168C (en) 2009-07-08 2019-04-09 Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
CN102470127A (zh) 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
EP2499282B1 (en) 2009-11-09 2015-04-22 NeuroGenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US20110129801A1 (en) * 2009-11-27 2011-06-02 Shikha Pramanik Barman Compositions and methods to prevent and treat dry socket post-operatively after tooth extraction surgery
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
RU2554087C2 (ru) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
US8710092B2 (en) * 2009-12-23 2014-04-29 Map Pharmaceuticals, Inc. Substituted indolo 4,3 FG quinolines useful for treating migraine
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
DK2542542T3 (en) 2010-03-02 2015-07-20 Axikin Pharmaceuticals Inc ISOTOPIC ENRICHED ARYL SULPHONAMIDE CCR3 ANTAGONISTS
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
TW201134820A (en) 2010-03-17 2011-10-16 Axikin Pharmaceuticals Inc Arylsulfonamide CCR3 antagonists
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
MX2012013879A (es) 2010-06-01 2013-04-03 Biotheryx Inc Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
CN103153309A (zh) 2010-06-01 2013-06-12 拜欧赛里克斯公司 使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
JP2011251944A (ja) * 2010-06-02 2011-12-15 Kansai Medical Univ 埋植用鎮痛製剤
SG186229A1 (en) 2010-06-07 2013-01-30 Novomedix Llc Furanyl compounds and the use thereof
US20130178522A1 (en) 2010-07-19 2013-07-11 James M. Jamison Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
CA2809022C (en) 2010-08-20 2017-01-03 Dr. Reddy`S Laboratories, Inc. Phospholipid depot
US20130225578A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
AU2011296046B2 (en) 2010-09-01 2015-05-14 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012030948A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
US20130225615A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012030894A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
ES2581840T3 (es) 2010-09-01 2016-09-07 Ambit Biosciences Corporation Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma
EP2663553B1 (en) 2010-09-01 2015-08-26 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
US20130303533A1 (en) 2010-09-01 2013-11-14 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
EP2611502A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
JP2013543512A (ja) 2010-10-11 2013-12-05 アクシキン ファーマシューティカルズ インコーポレーテッド アリールスルホンアミドｃｃｒ３アンタゴニストの塩
BR112013009743A2 (pt) 2010-10-22 2016-07-19 Reddys Lab Inc Dr uso de deposito de fosfolipidio viscoso estavel ao armazenamento para tratar ferimentos
US8865198B2 (en) 2010-10-25 2014-10-21 Dexcel Pharma Technologies Ltd. Method for treating a periodontal disease
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
EP2691389A1 (en) 2011-03-28 2014-02-05 MEI Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2012135160A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
US20140088103A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2012149287A1 (en) 2011-04-29 2012-11-01 Allergan, Inc. Solvent cast film sustained release latanoprost implant
BR112013033339A2 (pt) 2011-06-23 2016-08-16 Map Pharmaceuticals Inc análogos de fluorergolina
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US9381112B1 (en) 2011-10-06 2016-07-05 William Eric Sponsell Bleb drainage device, ophthalmological product and methods
TWI650321B (zh) 2011-10-14 2019-02-11 美商安比特生物科學公司 雜環化合物及其使用方法
WO2013095707A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
CA2859175A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
US8632489B1 (en) 2011-12-22 2014-01-21 A. Mateen Ahmed Implantable medical assembly and methods
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
CA2865349C (en) 2012-03-06 2021-07-06 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
EP2852586A1 (en) 2012-03-16 2015-04-01 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
EP2841098A4 (en) 2012-04-23 2016-03-02 Allertein Therapeutics Llc NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
AU2013255103B2 (en) 2012-05-02 2016-09-29 Pharmaxis Ltd. Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
IN2014MN02214A (ko) 2012-05-10 2015-07-17 Painreform Ltd
EP2825216B1 (en) 2012-06-12 2015-08-19 Ferrosan Medical Devices A/S Dry haemostatic composition
EP2861562B1 (en) 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
WO2014039748A1 (en) 2012-09-07 2014-03-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
JP6298468B2 (ja) 2012-10-16 2018-03-20 サーモディクス，インコーポレイテッド 創傷充填デバイスおよび方法
WO2014074765A2 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
CA2892227C (en) 2012-11-30 2020-12-15 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
EP2934143A4 (en) 2012-12-21 2016-06-15 Map Pharmaceuticals Inc NOVEL DERIVATIVES OF METHYSERGIDE
WO2014110305A1 (en) 2013-01-11 2014-07-17 Mayo Foundation For Medical Education And Research Vitamins c and k for treating polycystic diseases
CN105377355A (zh) 2013-03-14 2016-03-02 拇趾公司 治疗甲单元的感染、疾病或病症的方法
US9775853B2 (en) * 2013-03-15 2017-10-03 Biomet Manufacturing, Llc. Hemostatic compositions and methods
CA2907915C (en) 2013-04-03 2023-03-07 Allertein Therapeutics, Llc Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
US11173227B2 (en) 2013-05-22 2021-11-16 The Penn State Research Foundation Wound dressings and applications thereof
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
CN105358071B (zh) 2013-06-21 2018-07-31 弗罗桑医疗设备公司 真空膨胀的干组合物和用于保留该干组合物的注射器
KR20160055170A (ko) 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CN105828844B (zh) 2013-12-11 2019-09-27 弗罗桑医疗设备公司 包含挤出增强剂的干组合物
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
MX2016012097A (es) 2014-03-20 2017-04-27 Capella Therapeutics Inc Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
US10202398B2 (en) 2014-03-20 2019-02-12 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
EP3444011A1 (en) 2014-05-12 2019-02-20 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with emricasan
PL3148579T3 (pl) 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
RU2568919C1 (ru) * 2014-07-03 2015-11-20 Павел Васильевич Попрядухин Способ получения биосовместимого биодеградируемого пористого композиционного материала
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
US10201457B2 (en) 2014-08-01 2019-02-12 Surmodics, Inc. Wound packing device with nanotextured surface
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
US20170319548A1 (en) 2014-09-12 2017-11-09 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CN106999621B (zh) 2014-10-13 2020-07-03 弗罗桑医疗设备公司 用于止血和伤口愈合的干组合物
US20170354639A1 (en) 2014-10-24 2017-12-14 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
ES2834739T3 (es) 2014-12-11 2021-06-18 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
EP3237450B1 (en) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
AU2015371184B2 (en) 2014-12-24 2020-06-25 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
CN107428745A (zh) 2015-01-20 2017-12-01 Xoc制药股份有限公司 麦角灵化合物及其用途
EP3247357A4 (en) 2015-01-20 2018-07-11 Xoc Pharmaceuticals, Inc Isoergoline compounds and uses thereof
CN107428749B (zh) 2015-01-28 2020-07-24 上海复旦张江生物医药股份有限公司 取代的咪唑并[1,2-α]吡啶-2-基胺化合物及其药物组合物和使用方法
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
CN113603784A (zh) 2015-05-29 2021-11-05 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
US20190015396A1 (en) 2015-06-23 2019-01-17 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
BR112017027695A2 (pt) 2015-07-03 2018-09-04 Ferrosan Medical Devices As seringa para retenção e mistura de primeira e segunda substâncias
US20180200185A1 (en) 2015-07-23 2018-07-19 Novaflux, Inc Implants and constructs including hollow fibers
MX2018002315A (es) 2015-09-01 2018-04-11 Agenus Inc Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
PT3368534T (pt) 2015-10-30 2021-03-09 Neurocrine Biosciences Inc Ditosilato de valbenazina e polimorfos do mesmo
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
PT3394057T (pt) 2015-12-23 2022-04-21 Neurocrine Biosciences Inc Método sintético para a preparação de 2-amino-3-metilbutanoato de di(4-metilbenzenesulfonato) (s)-(2r,3r,11br)-3-isobutil-9,10-dimetoxi-2,3,4,6,7,11bhexaidro-1h-pirido[2,1,-a]lsoquinolin-2-ilo
SG11201805480TA (en) 2015-12-31 2018-07-30 Conatus Pharmaceuticals Inc Methods of using caspase inhibitors in treatment of liver disease
US10189808B2 (en) 2016-01-08 2019-01-29 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
EP3808346B1 (en) 2016-01-08 2023-07-19 Celgene Corporation Antiproliferative compounds for use in the treatment of leukemia
WO2017151836A1 (en) 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
EP3426352A4 (en) 2016-03-08 2019-11-13 Los Gatos Pharmaceuticals, Inc. CAMPTOTHECIN DERIVATIVES AND USES THEREOF
JP2019510085A (ja) 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
AU2017250086A1 (en) 2016-04-11 2018-09-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US20190160052A1 (en) 2016-05-13 2019-05-30 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
JP7267012B2 (ja) 2016-05-27 2023-05-01 アジェナス インコーポレイテッド 抗ｔｉｍ－３抗体及びその使用方法
JP2019525772A (ja) 2016-07-08 2019-09-12 スターテン・バイオテクノロジー・ベー・フェー 抗ａｐｏｃ３抗体およびその使用方法
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
AU2017326558B2 (en) 2016-09-19 2022-01-06 Mei Pharma, Inc. Combination therapy
MX2019003683A (es) 2016-10-11 2019-08-22 Agenus Inc Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
DK3528856T3 (da) 2016-10-18 2023-10-16 Univ Marquette Kompositmaterialer, der indeholder strukturelle polymerer og fotoreaktive nitrogenoxidfrigørende midler og anvendelser deraf til sårbandager
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7045724B2 (ja) 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
CA3042055A1 (en) 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
EP3548007A4 (en) 2016-12-01 2020-08-12 Ignyta, Inc. CANCER TREATMENT METHODS
US20200078352A1 (en) 2016-12-02 2020-03-12 Neurocrine Biosciences, Inc. Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
MD3551660T2 (ro) 2016-12-07 2024-03-31 Agenus Inc Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
SG11201906883SA (en) 2017-01-27 2019-08-27 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
AU2018220515B2 (en) 2017-02-17 2022-06-30 DayLife LLC Universal antivenom
SG11201906922TA (en) 2017-02-17 2019-09-27 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
MX2019011624A (es) 2017-03-27 2019-12-05 Celgene Corp Metodos y composiciones para la reduccion de la inmunogenicidad.
AU2018253176B2 (en) 2017-04-13 2023-02-02 Agenus Inc. Anti-CD137 antibodies and methods of use thereof
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
SI3618863T1 (sl) 2017-05-01 2023-12-29 Agenus Inc. Protitelesa proti tigitu in načini uporabe njih
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
BR112019025420A2 (pt) 2017-06-01 2020-06-16 Xoc Pharmaceuticals, Inc. Compostos policíclicos e usos destes
KR102472683B1 (ko) 2017-06-27 2022-12-01 주식회사 뉴라클사이언스 녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
US11560425B2 (en) 2017-06-27 2023-01-24 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating cancers
EP3645563A4 (en) 2017-06-27 2021-03-17 Neuracle Science Co., Ltd ANTI-FAM19A5 ANTIBODIES AND THEIR USES
JP7034499B2 (ja) 2017-06-27 2022-03-14 ニューラクル サイエンス カンパニー リミテッド 線維症の治療のための抗ｆａｍ１９ａ５抗体の用途
EP4265257A1 (en) 2017-09-01 2023-10-25 East Carolina University Combination of a j-series prostaglandin-ethanolamide and a checkpoint inhibitor for use in treating cancer
WO2019060322A2 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS AND KITS THEREOF
WO2019071021A2 (en) 2017-10-04 2019-04-11 The Regents Of The University Of California IMMUNOMODULATORY OLIGOSACCHARIDES
CN116492340A (zh) 2017-10-10 2023-07-28 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
US11701334B2 (en) 2018-01-10 2023-07-18 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
CA3094711A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
CN112424223A (zh) 2018-04-24 2021-02-26 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
ES2968412T3 (es) 2018-05-09 2024-05-09 Ferrosan Medical Devices As Método para preparar una composición hemostática
KR102661891B1 (ko) 2018-05-10 2024-05-23 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
BR112020024018A2 (pt) 2018-06-14 2021-02-23 Neurocrine Biosciences Inc. compostos inibidores de vmat2, composições e métodos relacionados a eles
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
MX2021000786A (es) 2018-07-20 2021-06-15 Pf Medicament Receptor para supresor de ig del dominio v de activación de células t (vista).
KR20210044817A (ko) 2018-08-15 2021-04-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
TWI834708B (zh) 2018-08-17 2024-03-11 美商文涵治療有限公司 Ag10之調配物
AU2019328276A1 (en) * 2018-08-31 2021-03-18 Rilento Pharma, Llc Pharmaceutical formulation and system and method for delivery
CA3113575A1 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
WO2020080496A1 (ja) * 2018-10-17 2020-04-23 東レ株式会社 止血材
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020163554A1 (en) 2019-02-06 2020-08-13 Dice Alpha, Inc. Il-17a modulators and uses thereof
MA55080A (fr) 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
US11597703B2 (en) 2019-03-07 2023-03-07 Histogen, Inc. Caspase inhibitors and methods of use thereof
CN114222803A (zh) 2019-05-20 2022-03-22 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
CA3146159A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
AU2020311404A1 (en) 2019-07-11 2022-03-03 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
BR112022004802A2 (pt) 2019-09-16 2022-08-23 Dice Alpha Inc Moduladores de il-17a e usos dos mesmos
JPWO2021112254A1 (ko) * 2019-12-06 2021-06-10
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
EP4093751A1 (en) 2020-01-22 2022-11-30 Outpace Bio, Inc. Chimeric polypeptides
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
US11529331B2 (en) 2020-05-29 2022-12-20 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
EP4236989A1 (en) 2020-11-02 2023-09-06 NeoImmuneTech, Inc. Use of interleukin-7 for the treatment of coronavirus
EP4240408A1 (en) 2020-11-05 2023-09-13 Neoimmunetech, Inc. Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
JP2024500377A (ja) 2020-12-14 2024-01-09 バイオセリックス， インコーポレイテッド Ｐｄｅ４分解剤、医薬組成物、及び治療的応用
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
EP4284377A1 (en) 2021-01-27 2023-12-06 Shy Therapeutics LLC Methods for the treatment of fibrotic disease
IL305752A (en) 2021-03-10 2023-11-01 Dice Molecules Sv Inc INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
EP4326721A1 (en) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
WO2022256437A1 (en) 2021-06-02 2022-12-08 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
WO2022266248A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2023055045A1 (ko) 2021-09-29 2023-04-06 주식회사 엔바이오스 코일드 코일 융합 단백질
US12017997B2 (en) 2021-10-22 2024-06-25 Prosetta Biosciences, Inc. Host-targeted pan-respiratory antiviral small molecule therapeutics
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
TW202342070A (zh) 2022-03-30 2023-11-01 美商拜奧馬林製藥公司 肌萎縮蛋白外顯子跳躍寡核苷酸
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
US20230331693A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the novel compounds
US20230416741A1 (en) 2022-05-05 2023-12-28 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
WO2023220640A1 (en) 2022-05-10 2023-11-16 Biotheryx, Inc. Cdk protein degraders, pharmaceutical compositions, and therapeutic applications
WO2023225665A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
US20240131005A1 (en) 2022-09-30 2024-04-25 Boulder Bioscience Llc Compositions and methods for treating non-hemorrhagic closed head injury
US20240209100A1 (en) 2022-10-21 2024-06-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
US20240174672A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridone Compounds
WO2024092040A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2430740A (en) * 1942-08-29 1947-11-11 Arthur E Sharples Therapeutic dressing
US2804424A (en) * 1951-04-24 1957-08-27 American Cyanamid Co Method of preparing a tetracycline type antibiotic-containing wound dressing
US2809149A (en) * 1954-12-23 1957-10-08 Cusumano Frank Ramo Antibiotic-impregnated gauze pads and method of making same
US2830011A (en) * 1957-02-07 1958-04-08 American Cyanamid Co Textile fabrics containing neomycin
US3642003A (en) * 1969-08-26 1972-02-15 Sutures Inc Sutures having long-lasting germicidal properties
US3987797A (en) * 1974-02-25 1976-10-26 Ethicon, Inc. Antimicrobial sutures
US4027676A (en) * 1975-01-07 1977-06-07 Ethicon, Inc. Coated sutures
US4024871A (en) * 1975-07-23 1977-05-24 Ethicon, Inc. Antimicrobial sutures
DE2650306A1 (de) * 1976-11-02 1978-05-03 Merck Patent Gmbh Antibakteriell wirkender wundverband und verfahren zu seiner herstellung
JPS5434493A (en) * 1977-08-17 1979-03-13 Tatsuo Fukuoka Fiber
US4265233A (en) * 1978-04-12 1981-05-05 Unitika Ltd. Material for wound healing
US4373519A (en) * 1981-06-26 1983-02-15 Minnesota Mining And Manufacturing Company Composite wound dressing
DE3212735A1 (de) * 1982-04-06 1983-10-06 Bayer Ag Membran fuer wirkstoff-freisetzungs- und wirkungstoff-resorptions-modelle
US5197977A (en) * 1984-01-30 1993-03-30 Meadox Medicals, Inc. Drug delivery collagen-impregnated synthetic vascular graft
MX163953B (es) * 1984-03-27 1992-07-03 Univ New Jersey Med Procedimiento para preparar una matriz biodegradable a base de colageno
US4837285A (en) * 1984-03-27 1989-06-06 Medimatrix Collagen matrix beads for soft tissue repair
US4847049A (en) * 1985-12-18 1989-07-11 Vitaphore Corporation Method of forming chelated collagen having bactericidal properties
US4643181A (en) * 1986-04-04 1987-02-17 Surgikos, Inc. Antimicrobial dressing or drape material
US5061689A (en) * 1986-12-24 1991-10-29 Bioderm, Inc. Zinc bacitracin containing wound dressing
US5064653A (en) * 1988-03-29 1991-11-12 Ferris Mfg. Co. Hydrophilic foam compositions
US5006071A (en) * 1988-05-09 1991-04-09 Carter Dewey G Technique for the prevention of alveolar osteitis
CA1340241C (en) * 1988-06-08 1998-12-15 Fountain Pharmaceuticals, Inc. Method for marking solvent dilution microcarriers
US5133965A (en) * 1988-06-08 1992-07-28 Fountain Pharmaceuticals, Inc. Dressing material having adsorbed thereon a solvent dilution microcarrier precursor solution
US5124155A (en) * 1988-06-21 1992-06-23 Chiron Ophthalmics, Inc. Fibronectin wound-healing dressings
US5116620A (en) * 1989-11-21 1992-05-26 Bruce A. Barber Antimicrobial wound dressing
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5196190A (en) * 1990-10-03 1993-03-23 Zenith Technology Corporation, Limited Synthetic skin substitutes
ATE224808T1 (de) * 1992-08-17 2002-10-15 Weyerhaeuser Co Verfahren zum binden von partikeln an fasern

Also Published As

Publication number Publication date
KR100382987B1 (ko) 2003-09-26
ATE244561T1 (de) 2003-07-15
RU2176525C2 (ru) 2001-12-10
DK0790823T3 (da) 2003-11-03
AU4364096A (en) 1996-06-19
DE69531254T2 (de) 2004-07-01
EP0790823B1 (en) 2003-07-09
MX9703912A (es) 1998-10-31
EP0790823A4 (en) 2000-07-12
DE69531254D1 (de) 2003-08-14
US5660854A (en) 1997-08-26
ES2202382T3 (es) 2004-04-01
AU698113B2 (en) 1998-10-22
JPH10511019A (ja) 1998-10-27
EP0790823A1 (en) 1997-08-27
WO1996016643A1 (en) 1996-06-06
CA2206259A1 (en) 1996-06-06
US5972366A (en) 1999-10-26

Similar Documents

Publication Publication Date Title
PT790823E (pt) Material libertador de farmaco para compressa ou implante cirurgico
EP0952171A3 (en) Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
EP0737703A3 (en) Hydrogel-forming , self-solvating absorbable polyester copolymers, and methods for use therefor
JP5638521B2 (ja) 温度を低減させる治癒用の創傷ドレッシング材
MXPA03003906A (es) Dispositivos de implante quirurgicos que tienen tejido de cicatriz reducida.
IL115721A (en) Device for the modulation of cell proliferation and wound healing and methods for its preparation
DE69502600T2 (de) Medizinische artikel
PT859596E (pt) Formulacoes em gel contendo factores de crescimento
DE69326418D1 (de) Medizinisch, hochwasserabsorbierende Polymere für Wundverbände und medizinische Binden
PT1069902E (pt) Utilizacao de fosfolipidos na producao de um medicamento para a prevencao de adesoes
DE69426530D1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
BR9809351A (pt) Tecido de bainha dérmica na cura de lesões
AU3401093A (en) Therapeutic agent for threatened abortion
RU2125862C1 (ru) Устройство для фиксации лечебных повязок
Travis Initial Experience Combining Negative Pressure Wound Therapy with Autologous Skin Cell Suspension and Meshed Autografts
ITRM990422A0 (it) Bendaggio infustito per protezione e/o immobilizzazione di parti lesedel corpo ad ausilio di medicazioni.
Green et al. Wound Sepsis Due to Postoperative Gauze Packing
Harrison New dressings and bandages
GB9901773D0 (en) A surgical medical dressing for the treatment of bodyburns and for wound healing
UA36267A (uk) Пристрій для лікування та реабілітації при гострому гематогенному остеомієліті та травматичних пошкодженнях нижніх кінцівок у дітей
UA32315A (uk) Спосіб накладання шкірного шва
GB2301841A (en) Medical articles
AUPM607794A0 (en) Protective covering for medical casts, plasters, bandages, dressings and the like